TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp

Stifel Financial Corp raised its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRXFree Report) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,133 shares of the company’s stock after purchasing an additional 3,733 shares during the period. Stifel Financial Corp owned 0.19% of TScan Therapeutics worth $494,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics during the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company bought a new stake in TScan Therapeutics during the 2nd quarter valued at $90,000. SG Americas Securities LLC acquired a new position in TScan Therapeutics during the 3rd quarter worth $78,000. Cornercap Investment Counsel Inc. bought a new position in shares of TScan Therapeutics in the second quarter worth $134,000. Finally, MetLife Investment Management LLC grew its stake in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Trading Up 6.9 %

Shares of TCRX stock opened at $3.11 on Friday. The stock has a 50-day simple moving average of $4.37 and a 200 day simple moving average of $5.53. The stock has a market capitalization of $165.98 million, a P/E ratio of -2.93 and a beta of 0.79. TScan Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRXGet Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.86 million. On average, sell-side analysts expect that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TCRX has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

Get Our Latest Analysis on TScan Therapeutics

About TScan Therapeutics

(Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Recommended Stories

Institutional Ownership by Quarter for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.